Tesamorelin vs Ipamorelin | Research Comparison
Research Use Only: All compounds referenced on this page are intended strictly for in-vitro laboratory research purposes only. Not for human consumption, medical treatment, or veterinary use. Read our full disclaimer.
Tesamorelin vs Ipamorelin | Research Comparison
Tesamorelin and Ipamorelin are both growth hormone secretagogues used in laboratory research, but they act on entirely different receptors and through distinct mechanisms. Tesamorelin is a GHRH analogue that activates GHRH receptors on pituitary somatotrophs, while Ipamorelin is a selective GHS-R1a agonist that activates the ghrelin receptor. This comparison helps researchers understand the mechanistic differences and select the appropriate compound for their experimental design.
At a Glance
| Property | Tesamorelin | Ipamorelin |
|---|---|---|
| Receptor target | GHRH receptor (GHRHR) | Ghrelin receptor (GHS-R1a) |
| Peptide class | GHRH analogue (44 AA) | GH secretagogue pentapeptide (5 AA) |
| Mechanism | Stimulates GH synthesis and pulsatile release via GHRHR | Stimulates GH release via GHS-R1a; cAMP/PKA and IP3/PKC pathways |
| Selectivity | GHRHR-selective | Highly selective GHS-R1a; minimal cortisol/prolactin effect |
| Primary research focus | Visceral adipose tissue, GH/IGF-1 axis, hypothalamic-pituitary research | GHS-R pharmacology, GH pulse dynamics, ghrelin receptor biology |
| Cortisol/ACTH effect | Minimal at research concentrations | Minimal — high selectivity profile |
| Molecular weight | ~5136 Da | ~711 Da |
| Combined use | Used as standalone GHRHR agonist | Frequently combined with CJC-1295 for dual-receptor GH research |
Mechanism of Action
Tesamorelin
Tesamorelin is a full-length GHRH analogue (44 AA) with a trans-3-hexenoic acid N-terminal modification that confers DPP-IV resistance. It binds to GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and pulsatile secretion via cAMP/PKA signalling. In laboratory models, Tesamorelin-stimulated GH release drives hepatic IGF-1 production, enabling study of the complete GH/IGF-1 axis including downstream anabolic and lipolytic signalling.
Ipamorelin
Ipamorelin binds selectively to GHS-R1a (ghrelin receptor) on somatotroph cells, stimulating GH release through a mechanism distinct from GHRHR signalling. Its high receptor selectivity means it does not significantly stimulate ACTH, cortisol or prolactin in laboratory models. Ipamorelin is used to study GHS-R1a pharmacology, receptor internalisation and the ghrelin-independent GH secretagogue pathway in isolation from GHRHR-mediated effects.
Key Research Differences
Receptor Pathway
The fundamental distinction is receptor target. Tesamorelin activates GHRHR — the receptor for endogenous GHRH — while Ipamorelin activates GHS-R1a, the ghrelin receptor. These are independent signalling pathways. For experiments studying GHRHR pharmacology or native GHRH receptor interactions, Tesamorelin is the appropriate tool. For GHS-R1a pharmacology and ghrelin receptor biology, Ipamorelin is preferred.
Research Application Focus
Tesamorelin is primarily used in laboratory models studying visceral adipose tissue regulation, GH-mediated lipolysis and hypothalamic-pituitary axis function. Its full-length GHRH sequence makes it a close structural analogue to endogenous GHRH. Ipamorelin is primarily used in GH secretagogue pharmacology research, ghrelin receptor biology and combination GH secretagogue studies alongside CJC-1295 No DAC.
Combination Research
Ipamorelin is the standard GHS-R1a companion to CJC-1295 No DAC in dual-receptor GH secretagogue research. Tesamorelin is not typically used in combination protocols — it is used as a standalone GHRHR agonist. For researchers studying synergistic GH secretagogue effects via dual receptor activation, Ipamorelin (with CJC-1295) is the appropriate design. For standalone GHRHR research, Tesamorelin is preferred.
Choosing Between Them for Research
For GHRHR pharmacology, visceral adipose tissue research, full-length GHRH receptor interactions or hypothalamic-pituitary axis studies, Tesamorelin is the appropriate tool. For GHS-R1a pharmacology, ghrelin receptor biology, selective GH secretagogue research or combination protocols with CJC-1295, Ipamorelin is preferred. Both are available from Solatide Biosciences, independently third-party tested to ≥99% purity.
Related Resources
Research Use Only: All compounds are manufactured for in-vitro laboratory research and are not intended for human consumption, medical use, or veterinary applications. Full disclaimer.